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Abstract
Background: The use of self-report measurements in clinical settings is increasing. However, in patients with
limitations that interfere with reliable self-assessment such as cognitive impairment or mood disturbances, as may
be the case in multiple sclerosis (MS), data collection might be problematic. In these situations, information
obtained from proxy respondents (e.g. partners) may replace self-ratings. The aim of this study was to examine
the value of proxy ratings at separate points in time and to assess patient-proxy agreement on possible changes
in disease impact of MS.
Methods: Fifty-six MS patients and their partners completed the Multiple Sclerosis Impact Scale (MSIS-29) at
baseline and follow-up, two years later. Patient-proxy agreement was assessed at both time points by calculating
intraclass correlation coefficients (ICCs), exact and global agreement and the mean directional differences
between groups. Agreement of change over time was assessed by calculating ICCs between change scores. In
parallel, global ratings of both patients and proxy respondents of the extent to which the patient had improved
or deteriorated over the past two years were collected to validate possible changes on the MSIS-29.
Results: At both time points, agreement on the physical scale was higher than agreement on the psychological
scale (ICCs at baseline were 0.81 for the physical scale and 0.72 for the psychological scale; at follow-up, the ICC
values were 0.86 and 0.65 respectively). At follow-up, statistically significant mean differences between patients
and proxies were noted for the physical scale (-4.8 ± 12.7, p = 0.006) and the psychological scale (-8.9 ± 18.8, p
= 0.001). Agreement between change scores on the MSIS-29 was fair (ICC < 0.60). Our analyses suggest that the
validity of measuring changes over time might be better for proxy respondents compared to patients.
Conclusion: Proxy respondents could act as a reliable source of information in cross-sectional studies.
Moreover, results suggested that agreement on change over time might be better for proxy respondents
compared to patients. Although this remarkable finding should be interpreted cautiously because of several
limitations of the study, it does plead for further investigation of this important topic.
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Outcomes of health status measurements are becoming
increasingly important in evaluating the treatment effect
of clinical trials and could potentially play an important
role in medical decision-making. Health status measure-
ments can be used to measure cross-sectional differences
in health status between patients at a certain point in time
or longitudinal changes in health status within patients
over a period of time [1]. Data collection is mainly per-
formed by using self-report questionnaires to capture the
patient's perspective. In recent years, several self-report
measures have been developed to assess impairment and
disability of Multiple Sclerosis (MS). Of those available,
the Multiple Sclerosis Impact Scale (MSIS-29) is both dis-
ease specific and rigorously evaluated for its psychometric
properties [2-4]. The MSIS-29 measures the disease
impact of MS on daily life of MS patients. Although it is
generally agreed that the patient is the best rater of their
own health status, conditions such as cognitive impair-
ment or mood disturbance might lead to inaccurate self-
report or even loss of information due to missing data.
This could result in data which are not representative for
the patient population of interest. Exclusion of such
patients, a sometimes chosen approach, may cause bias in
the assessment of health status.
In MS, cognitive impairment is an important issue [5].
Research has shown that cognitive deficits are present in
40 to 60 percent of MS patients [5,6]. During the different
disease stages and subtypes of MS, variable cognitive pro-
files are seen and disturbances may start already early in
the disease, even before serious physical disability has
developed [5,7]. Mood disturbances (depression and anx-
iety) may also occur during the disease course of MS.
Depression is common in approximately half of the MS
patients [8]. Anxiety disorders present themselves in
about 36% of the MS patients [9]. The frequent use of self-
report measurements and the common presence of cogni-
tive impairment and mood disturbances could cause a
problem in MS research. A possible solution for this prob-
lem might be the incorporation of a third person, a so-
called proxy respondent who can provide information on
the health status of the patient that otherwise would be
inaccurate or even lost [10]. The use of proxy respondents
is based on the assumption that a proxy respondent is
capable of assessing the values and preferences of the
patient. Besides this, the proxy respondent should be able
to identify any changes that might occur over time in the
patient's view [11]. So far, little is known about the value
of proxy respondents in MS. A previously performed
cross-sectional study on patient-proxy agreement in a
small MS sample indicated that partners might be useful
sources of information when assessing the impact of MS
on daily life of patients [12]. Although this is an impor-
tant finding, the stability of these findings over time
remains to be investigated. The validity of measuring
changes over time in a longitudinal setting, for example in
clinical trials in which the effect of treatment is assessed
over time, is especially important. Several studies have
examined patient-proxy agreement on change over time
in a longitudinal setting, but diverse results were reported
[13-19]. Sneeuw et al. provided support for the respon-
siveness to change of significant others and health care
providers [15,18]. A few studies indicated an improve-
ment of patient-proxy agreement over time when patients
improved or became stable over time [13,14,19]. Yet,
other studies reported contrary results by showing poor
patient-proxy agreement on changes over time [16,17].
Until now, no longitudinal studies on patient-proxy
agreement were performed in MS.
The objective of this study was to examine patient-proxy
agreement on the disease impact of MS on daily life at two
separate points in time, and to assess patient-proxy agree-
ment on possible changes between those two time points.
Methods
Study design
This prospective longitudinal cohort study was conducted
at the MS Center of the VU University Medical Center
(Amsterdam, The Netherlands). Data was collected at
baseline and two years after baseline. The medical ethical
committee of the VU University Medical Center approved
the study protocol and informed consent was obtained
from all participants prior to participation.
Measures and procedures
Baseline
At baseline, patients and proxy respondents were recruited
from an ongoing study at the MS Center. This was a case-
control study in Dutch MS patients and matched healthy
controls to examine whether serum vitamin D levels are
associated with the risk of MS. Inclusion criteria for both
patients and healthy controls were: written informed con-
sent and age between 18 and 75 years. Exclusion criteria
included (medical) conditions that were thought to
highly influence the serum concentrations of vitamin D
metabolites. In addition, healthy controls should have a
negative family history regarding MS. In case the healthy
control person was the partner of the patient, he or she
was asked to participate as a proxy respondent in the
present study.
Both patients and proxy respondents were asked to com-
plete the MSIS-29 [see additional file 1]. This was done
independently from each other in separate rooms to avoid
possible discussion between patients and proxy respond-
ents. The MSIS-29 is a self-report measurement which
assesses the physical and psychological impact of MS onPage 2 of 9
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respectively. Scores on the individual items are added and
transformed to a 0–100 scale, thereby generating two
summary scores of both scales. Higher scores indicate
worse health [2]. High values for test-retest reliability were
found in the initial validation of the MSIS-29, which sup-
port use in longitudinal studies (intraclass correlation
(ICC) of 0.94 and 0.87 for the physical scale and the psy-
chological scale, respectively). A possible interpretation of
MSIS-29 scores could be to categorise scores of 0–19 as
'no problems', 20–39 as 'few problems', 40–59 as 'moder-
ate problems', 60–79 as 'quite a few problems' and 80–
100 as 'extreme problems'[20]. For this study, the Dutch
version of the MSIS-29 was used, which is an in-house
translation of the original English version that was subse-
quently validated in a large study across eight European
countries [21]. The partners completed a modified version
of the MSIS-29 in which all items were phrased in the
third person perspective. The proxy respondents were
instructed to assess the patient as the proxy thought the
patient would rate his or herself [22]. They had to com-
plete the MSIS-29 keeping in mind the following ques-
tion: 'How do you think the patient experiences the
impact of MS on his/her life?' A psychometric evaluation
of the MSIS-29, when completed by proxy respondents,
was previously performed and the results were supportive
towards using the MSIS-29 in a proxy sample [23]. Test re-
test reliability showed an ICC of 0.87 for the physical scale
and an ICC of 0.83 for the psychological scale. Addition-
ally, data on disability, mood and cognition, were col-
lected in the patient sample to investigate possible
influence of these factors on mean differences between
patients and proxy respondents. Cognitive performance
was assessed by applying the Brief Repeatable Battery of
Neuropsychological Tests (BRB-N) [5,24]. The BRB-N is a
test battery consisting of five tests, each measuring a differ-
ent area of cognitive functioning, including verbal learn-
ing and memory, visuospatial learning, attention and
concentration, information processing and semantic ver-
bal fluency. The Hospital Anxiety and Depression Scale
(HADS) was used to assess the mood status of the patient.
The HADS is a 14-item screening instrument which is
used to screen for possible anxiety disorders and depres-
sion. It contains two 7-item scales: one for anxiety and
one for depression both with a score range of 0–21 [25].
Both domains were used to define the mood status of the
patient. A trained doctor assessed neurological impair-
ment and disability with the Expanded Disability Status
Scale (EDSS) [26]. MS subtype was available for all
patients.
Follow-up
Two years after baseline assessment, patients and proxy
respondents were contacted again and invited to partici-
pate in the follow-up study. According to the preference of
the patient, the visit was scheduled at the MS Center or a
trained medical student visited the patient and partner at
home. During assessment, both patient and proxy
respondent completed the MSIS-29 and data on mood
status of the patient was collected by the HADS. The proxy
respondent was asked to complete the MSIS-29 in a sepa-
rate room of the house. Although the aim was that the
partner was present during the follow-up visit, this was
not always possible. When the partner was not present,
the questionnaires were given along with the patient to
take home or were left after the home visit with explicit
instructions that they had to complete the questionnaires
independently from the patient. Due to practical restric-
tions the BRB-N was not performed at follow-up. In the
case of a home visit, the EDSS score was assessed by using
an interview-based questionnaire. This interview-based
questionnaire was developed for patients who are unable
to continue visiting the outpatient clinic for follow-up
measurement in longitudinal studies or clinical trials [27].
Additionally, global ratings of both patients and proxy
respondents of the extent to which the patient stayed sta-
ble, improved or deteriorated over the past two years,
were collected to validate possible changes on the MSIS-
29. These ratings were collected by using a so-called 'tran-
sition question', which requires the subject to compare
their prior health status to their current situation [28]. In
this study, patients were asked: 'How do you feel, regard-
ing to your MS, in comparison to two years ago?' Answer
categories included the following items: 'a lot worse' –
'worse' – 'the same' – 'better' – 'a lot better'. The proxy
respondent was also asked how they thought the patient
felt in comparison to two years ago.
Data analyses
Patient-proxy differences and agreement at baseline and follow-up
The data were initially analysed separately for baseline
and follow-up for which several statistical strategies were
used.
First, mean differences (mean patient scores minus mean
proxy scores) between both groups were calculated for
both scales to get insight in the direction and magnitude
of these differences. Paired student's t-tests were used to
examine whether these differences were statistically signif-
icant and would therefore provide evidence of systematic
over- or underreporting by one group. Such systematic
bias can occur when, for example, proxy respondents con-
sistently report a lower or higher impact of MS than the
patients themselves. In this case there can still be an excel-
lent correlation between the two groups but a poor agree-
ment. In line with other literature on proxy
measurements, the effect size (d) was used to estimate the
magnitude of the systematic differences [29]. The effect
size can be estimated by standardising the mean differ-
ences to their standard deviations (mean directional dif-Page 3 of 9
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calculating effect sizes (d) used in paired t-tests it seems
reasonable to apply the same classification: d = 0.20 indi-
cates a small bias, d = 0.50 indicates a moderate bias, d =
0.8 indicates a large bias [29].
Patient-proxy agreement was also examined by calculat-
ing the correlation between ratings of patients and proxy
respondents. An appropriate statistic is the intraclass cor-
relation coefficient (ICC), which is calculated as the ratio
of the variance between subjects (variance of interest) and
the total variance [30]. For this study the two-way random
model for absolute agreement was used [31]. Standards
for interpreting ICC values are arbitrary but one can apply
the standard reliability criteria of an ICC > 0.70, which is
adequate and an ICC > 0.80 is preferred [32]. In addition,
patient-proxy agreement was assessed by calculating the
percentages of exact agreement and global agreement on
responses between patient-partner pairs. Exact agreement
is the percentage of patient responses identical to the
responses of the proxy (e.g. both patient and proxy
respondent score 2 on item 12). Global agreement refers
to the percentage of agreement within one response cate-
gory in both directions (e.g. patient scores 2 on item 12
and the proxy respondent scores 1, 2 or 3 on this item)
[30].
Patient-proxy agreement on change over time
To evaluate patient-proxy agreement on change over time,
mean change scores (follow-up minus baseline) on the
MSIS-29 were calculated for both patients and proxy
respondents. Subsequently, agreement on possible
change over time was assessed by calculating ICCs
between the mean change scores.
Next, the items of the transition questions were dichot-
omised into patients who deteriorated ('a lot worse' –
'worse') and those who did not ('the same' – 'better' – 'a
lot better'). The latter group is in the remainder of this
paper indicated as 'stable'. The same was done for proxy
respondents who thought the patients deteriorated or
stayed 'stable' over the last two years. A Kappa coefficient
(κ) was calculated to assess a chance corrected agreement
for the transition ratings of both groups.
Finally, both patient and proxy samples were divided
according to the dichotomous transition question (deteri-
orated – stable). Again, change scores were calculated for
both groups in order to see if the change scores on the
MSIS-29 were in concordance with the transition ratings.
Factors affecting patient-proxy differences
Different variables that could have influenced on patient-
proxy differences at baseline and follow-up were investi-
gated. These variables included: disability, mood, cogni-
tion of the patient and gender of the proxy respondent.
For each variable the sample was divided into different
subgroups, according to variable-specific criteria. Subse-
quently, the mean directional differences between
patients and proxy respondents were calculated for the
corresponding MSIS-29 scores in each subgroup. One-way
ANOVA analyses were performed to see if these subgroups
differed significantly from each other.
The EDSS score of the patient was divided according to the
following classification: 0.0–3.5; 4.0–6.0; 6.5–8.0. Possi-
ble influence of mood was investigated by dividing the
sample into subgroups defined on the HADS score. The
following criteria were used: ≤ 7 = no clinically levels of
anxiety and depression; 8 – 10 = clinically borderline; ≥ 11
= clinically definite levels of anxiety and depression [33].
In order to see if cognitive impairment was of influence,
the sample was divided into three subgroups: normal
BRB-N scores, 1 or 2 abnormal BRB-N scores and 3 or
more abnormal BRB-N scores. Cognitive impairment on
one of the tests of the BRB-N was defined as two standard
deviations below the mean reported for healthy subjects
[5,24]. Although there is no universal consensus of how to
define or diagnose cognitive impairment in MS, the fre-
quently used criteria of three or more abnormal tests
scores on the BRB-N was used to define cognitive impair-
ment [34]. Finally, the sample was divided according to
the gender of the proxy.
Results
Study sample
Follow-up data was available for 56 of the 59 patient-
proxy couples. Reasons for 'lost to follow-up' were that
two patients were reluctant to participate due to their busy
schedules and one patient was withdrawn from the study
by his partner due to severe cognitive impairment of the
patient. The patients and proxy respondents had a mean
follow-up duration of 750 days, which equals a time
period of 2.06 years (range years: 1.8 – 2.3, SD = 36.2
days). All patients and proxies were living together, except
for one couple. This couple lived together only during
weekends; on the other days of the week the patient stayed
in a rehabilitation center.
Table 1 lists the characteristics of the patients and proxy
respondents, the mean total scores on the physical and
psychological scale of the MSIS-29 and the number of
patients in each subgroup of the EDSS, the HADS and the
BRB-N at baseline and follow-up.
Patient-proxy differences and agreement at baseline and 
follow-up
Table 2 shows the mean directional differences between
patients and proxy respondents and values of agreement,
at baseline and follow-up.Page 4 of 9
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cal score was minimal (-0.8 ± 15.3) and there was no evi-
dence for systematic bias (d = 0.1). The mean directional
difference for the psychological scale was -4.4 ± 17.0, but
this difference was not statistically different. At follow-up,
statistically significant mean differences were seen for the
physical scale (-4.8 ± 12.7, p = 0.006) and the psycholog-
ical scale (-8.9 ± 18.8, p = 0.001). However, both scales
showed moderate systematic bias.
ICCs for the physical scale were larger than 0.80, at base-
line and follow-up. At both time points, the ICC for the
psychological scale was lower than the ICC for the physi-
cal scale: 0.72 at baseline and 0.65 at follow-up.
At baseline, there was an exact agreement of 47.4% on the
physical scale and 83.1% of the patients and proxy
respondents answered within one adjacent category. Exact
and global agreement for the psychological scale was
44.6% and 82.5%, respectively. At follow-up, the average
proportion of exact agreement on the physical scale was
Table 2: Patient-proxy differences and agreement on baseline and follow-up
MSIS-29 Directional differencea 
(Mean ± SD) (95% CI)
d ICC (95% CI) Exact agreement 
(%)
Global agreement 
(%)
Baseline (n = 59) Physical scale -0.8 ± 15.3 (-4.9 – 3.2) 0.1 0.81 (0.70–0.88) 47.4 83.1
Psychological scale -4.4 ± 17.0 (-8.7 – 0.1) 0.3 0.72 (0.55–0.82) 44.6 82.5
Follow-up (n = 56) Physical scale -4.8 ± 12.7b (-8.2 – 1.4) 0.4 0.86 (0.76–0.92) 43.3 82.6
Psychological scale -8.9 ± 18.8b (-14.0 – 3.9) 0.5 0.65 (0.42–0.79) 38.1 81.0
a Patient minus proxy respondent; negative scores indicate that the proxy scores higher than the patient.
b Statistically significant difference between mean score of patient and proxy groups (P < 0.05)
MSIS-29: Multiple Sclerosis Impact Scale, SD: standard deviation, ICC: intraclass correlation coefficient, d: effect size, CI: confidence interval
Table 1: Characteristics of patients and proxy respondents at baseline and follow-up
Baseline Follow-up
Patients Proxy respondents Patients Proxy respondents
Total 59 59 56 56
Female (n) 41 19 40 17
Age (years)* 47.8 (8.9) 49.2 (9.0) 50.6 (9.1) 52.4 (9.9)
Years since MS onset* 12.8 (7.2) - 14.8 (7.4) -
Type of MS (n)
Relapsing-remitting 28 - 26 -
Secondary progressive 19 - 18 -
Primary progressive 10 - 10 -
Other 2 - 2 -
MSIS-29
Physical scale* 42.0 (24.1) 42.8 (25.8) 45.1 (25.3) 50.0 (25.8)
Psychological scale* 29.0 (22.6) 33.3 (22.5) 30.1 (23.5) 39.0 (24.4)
EDSS (median) 4.5 _ 5.5 _
HADS (n, depression/anxiety)
≤ 7 42/37 _ _ _
8–10 7/10 _ _ _
≥ 11 10/12 _ _ _
BRB-N (n)
0 abnormal scores 46 _ _ _
1–2 abnormal scores 6 _ _ _
≥3 abnormal scores 5 _ _ _
Missing 2 _ _ _
*Values are mean (SD)
MSIS-29: Multiple Sclerosis Impact Scale, EDSS: Expanded Disability Status Scale, HADS: Hospital Anxiety and Depression Scale, BRB-N: Brief 
Repeatable Battery of Neuropsychological TestsPage 5 of 9
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responses were seen for 38.1% of the patients and proxy
respondents and 81.0% responded within one adjacent
category.
Patient-proxy agreement on change over time
Table 3 shows the mean change scores (follow-up minus
baseline) for both scales, in both groups. Positive scores
indicate a higher mean scale score on the MSIS-29 at fol-
low-up. Change scores for both patients and proxy
respondents were positive, indicating a higher score on
the MSIS-29 at follow-up. Patients had a mean change
score of 3.0 ± 13.5 on the physical scale. A small mean
change score was seen on the psychological scale (1.0 ±
16.4). The change scores for the proxy respondents on the
physical and the psychological scale were 7.1 ± 16.6 and
5.6 ± 22.5, respectively. The mean change scores of the
proxy respondents on both scales appeared to be larger
than the mean change scores of the patient sample. How-
ever, independent t-test showed that these differences
were not statistically significant (p ≥ 0.05).
ICCs between the mean change scores are displayed in the
last line of table 3; poor agreement (ICC = 0.30; 95% CI:
0.06–0.53) was seen for the physical scale and fair agree-
ment was seen for the psychological scale (ICC = 0.42;
95% CI: 0.19–0.61).
Data on the transition ratings showed that 39 patients
judged their situation as deteriorated as opposed to 17
patients who indicated that they did not deteriorate in the
past two years. In the proxy sample, also 39 proxies indi-
cated that the patient deteriorated and 17 proxies indi-
cated that the patients had not deteriorated. It should be
emphasised that, although the distribution of transition
ratings numbers was identical in both samples, they did
not relate to the same patient-proxy couples. In fact, the
strength of the agreement between the transition ratings
was only moderate (κ = 0.58). Table 4 shows the mean
change scores according to transition ratings of patients
and proxy respondents. It can be observed from table 4
that, although the patients indicated that they stayed sta-
ble (or even improved) over the past two years, they did
show a larger mean change score on both scales when
compared to patients who indicated that they deteriorated
over the past two years. The opposite is seen in the proxy
sample: proxy respondents who indicated that the
patients stayed stable (or improved) over the past two
years had smaller change score on the MSIS-29 when
compared to proxies who indicated that patients had dete-
riorated.
Factors affecting patient-proxy differences
At baseline and follow-up, one-way ANOVA analyses
showed no significant differences between the three sub-
groups of the EDSS and the HADS. There were also no sig-
nificant differences between the subgroups of the BRB-N
scores at baseline.
Moderate systematic bias was seen on the psychological
scale of the MSIS-29 for female proxy respondents, both at
baseline (-8.37 ± 17.1, p = 0.047, d = 0.5) and follow-up
(-10.8 ± 17.5, p = 0.022, d = 0.6). There was no gender bias
seen on the physical scale.
Discussion
The aim of this study was two-fold; to examine patient-
proxy agreement on the impact of MS on daily life at dif-
ferent points in time and to get more insight in patient-
proxy agreement on change over time.
The positive mean differences that were found at baseline
and follow-up indicated a tendency for proxy respondents
to report more disease impact of MS than the patient did
themselves. This tendency of reporting more symptoms
and lower levels of functioning by proxy respondents
compared to the patients themselves, is in line with other
studies on this topic [10,35]. In contrast to some of the
other longitudinal proxy studies [13,14,19] we did not see
an improvement in agreement over time. Mean direc-
tional differences at follow-up were actually statistically
significant for both the physical and the psychological
scale, which points towards systematic overestimation by
proxy respondents. Effect sizes showed that the magni-
tude of this bias was moderate for both scales.
At both time points, the ICC showed good agreement for
the physical scale and a slightly lower but still adequate
agreement for the psychological scale. Both ICCs and the
percentages for exact and global response agreement were
lower for the psychological scale than for the physical
scale, indicating a lower agreement for the psychological
Table 3: Change scores on both scales of the MSIS-29
∆ MSIS-29 physical scalea (mean ± SD) ∆ MSIS-29 psychological scalea (mean ± SD)
Patient 3.0 ± 13.5 1.0 ± 16.4
Proxy 7.1 ± 16.6 5.6 ± 22.5
ICC ∆ MSIS-29 (95% CI) 0.30 (0.06–0.53) 0.42 (0.19–0.61)
a Mean score at follow-up minus mean score at baseline
MSIS-29: Multiple Sclerosis Impact Scale, CI: confidence intervalPage 6 of 9
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agreement studies that better agreement is demonstrated
when it comes to the more objective, more observable
questions but less agreement is seen when it comes to the
more subjective, less observable questions [10,11].
With respect to change over time, proxy respondents
appeared to report a larger change than the patients did
themselves, but these differences were not significant. On
the other hand, ICCs between the change scores on the
MSIS-29 were poor, indicating a low level of patient-proxy
agreement on the change scores. However, since an ICC is
based on the variance of the sample, a lack of variance in
change scores could also have caused the low ICCs, rather
than lack of patient-proxy agreement [36]. Moreover, part
of the patient sample was rather stable over the study
period. Especially in these cases, differences between the
two measurements are mainly caused by measurement
error or random error, which will lower the calculated
ICCs. Other studies showed contrasting results ranging
from poor agreement [14,16,17] to moderate agreement
on change over time [19,37].
When the change scores were validated against the transi-
tion ratings, a remarkable finding was observed; while
patients indicated that they stayed stable over the preced-
ing two years, they showed a larger increase on the MSIS-
29 when compared to patients who indicated that they
had deteriorated over that time. These patients showed a
lower increase on the MSIS-29. When the same compari-
son was made for the proxy respondents it was seen that
the transition ratings of the proxy respondents were in
concordance with the mean change scores. These results
could suggest that the ability to rate possible changes over
time might be better for proxy respondents. Although the
loss to follow-up was limited in this study, the effect of
non-random drop out is hard to exclude.
Besides this, possible methodological issues concerning
transition ratings could compromise results [28].
Research has shown that it appears to be very difficult for
the patient to compare their initial health state to their
current health status and that their judgement of change is
actually based on their current health status. It is not
known whether the change scores or the transition ratings
are more accurate and if they actually measure the same
concept [38]. The differences between the transition rat-
ings and the change scores could also reflect measurement
error or may be due to different perceptions of the mean-
ing of a change [38]. Also, the patients in this sample
stayed relatively stable over the two years. The change
scores that were measured could therefore have consisted
mostly of measurement error instead of actual change in
disease impact. Moreover, in a longitudinal setting, one
should also be aware of the possible occurrence of
response shift which may influence the results.
Several other factors that could possibly have influenced
the mean directional differences, and could therefore have
caused systematic bias, were examined. Disability and
mood status (anxiety and depression) did not seem to sig-
nificantly influence the differences between patients and
proxy respondents at baseline and follow-up. Cognitive
performance did not have an effect at baseline. The find-
ing that disability, cognitive functioning and mood did
not seem to have an influence should be interpreted with
caution, since these findings are based on a small sample.
This could have resulted in a low power and therefore
false negative findings (Type II error). Future research
focusing on proxy measurements in MS should therefore
be performed in larger and/or more cognitively impaired
samples. Unfortunately, there were no data on cognitive
performance at follow-up so it is unclear whether there
was an effect. In contrast to male proxy respondents,
female proxy respondents seemed to consistently overes-
timate the psychological impact of MS at baseline and fol-
low-up. There was no gender bias found for the physical
Table 4: mean changes scores on both scales of the MSIS-29 according to transition ratings
Patient
Transition rating ∆ MSIS-29 physical scalea (mean ± SD) ∆ MSIS-29 psychological scalea (mean ± SD)
Stableb (n = 17) 4.3 ± 12.8 1.8 ± 19.2
Deterioratedc (n = 39) 2.4 ± 14.0 0.6 ± 15.2
Proxy
Transition rating ∆ MSIS-29 physical scalea (mean ± SD) ∆ MSIS-29 psychological scalea (mean ± SD)
Stableb (n = 17) 5.4 ± 13.5 2.0 ± 18.6
Deterioratedc (n = 39) 7.8 ± 17.9 7.1 ± 24.1
a Mean score at follow-up minus mean score at baseline
b combines the transition ratings 'the same' – 'better' – 'a lot better', indicating both stability and improvement
c combines the transition ratings 'worse' and 'a lot worse'.
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der on patient-proxy differences and this finding should
therefore be considered with caution. Another limitation
of this study was the use of partners as proxies. Whether
these results are also applicable on other proxies, such as
healthcare providers, also remains to be investigated.
Conclusion
Findings from this study show acceptable levels of
patient-proxy agreement both at baseline and follow-up,
especially on the physical scale. Proxy respondents could
therefore play a supportive role in cross-sectional studies
by providing valuable information in situations when the
patient is not capable due to limitations that interfere with
reliable self-assessment. The level of patient-proxy agree-
ment on change of disease impact appeared to be low. The
finding that proxy respondents were better assessors of
change over time is striking, but should be interpreted by
taking into account the limitations of this study. Nonethe-
less, the value of proxy respondents in MS research
remains an important issue and further research into the
validity and reliability of proxy respondents in longitudi-
nal studies is needed.
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